Loading organizations...
§ Venture Capital · New York City, NY, USA
A global HealthTech and Life Sciences venture capital fund based in Israel, investing in biopharma, digital health, and medtech.
Founded in 2015 by Marius Nacht and Yair Schindel, aMoon Fund is a venture capital firm based in Ra'anana, Israel, investing in early- and late-stage health technology and life sciences companies. As Israel's largest health-tech venture capital fund, it manages over $1.3 billion in assets under management, supported by a global network of more than fifty industry experts. The firm operates multiple investment strategies across biopharma, digital health, and medical technology, including a seed-stage Velocity Fund, a Growth Fund for clinical-stage startups, and an Edge Fund for public equities. Its specific capital pools include a $750 million Growth Fund and a $340 million early-stage Velocity II fund that closed in 2022. The firm has backed notable portfolio companies such as Seer, MDClone, and CartiHeal, which was acquired by Smith+Nephew for up to $330 million in November 2023.
Key people at aMoon Fund.
Key people at aMoon Fund.
aMoon Fund is a leading venture capital firm focused on investing in biopharma, digital health, and medical technology companies that leverage cutting-edge science and technology to address significant global healthcare challenges. Their mission centers on accelerating the transformation of healthcare from reactive treatment to predictive, preventive, and personalized care. They invest across early and late stages through their aMoon Velocity and aMoon Growth platforms, targeting disruptive solutions for high unmet medical needs. aMoon plays a pivotal role in the startup ecosystem by bridging portfolio companies with global tech, finance, and medical research hubs, enabling faster innovation and market impact[1][2][3].
Founded in 2017 by Dr. Yair Schindel, a physician and entrepreneur, and Marius Nacht, a serial entrepreneur and cofounder of Check Point, aMoon was established to seize a unique moment in healthcare innovation. The founders recognized the vast unmet needs in healthcare, inspired in part by personal experiences and the potential of HealthTech to revolutionize care delivery. The firm has evolved to become Israel’s largest HealthTech VC fund, leveraging the country’s scientific talent and startup culture to back transformative healthcare ventures[2][5].
aMoon is riding the wave of convergence between technology and biology, a trend that is reshaping healthcare globally. The timing is critical as advances in genomics, AI, digital health, and personalized medicine create unprecedented opportunities to improve outcomes and reduce costs. Market forces such as aging populations, rising chronic diseases, and demand for more efficient healthcare delivery favor aMoon’s investment focus. By fostering collaboration across sectors and geographies, aMoon influences the broader ecosystem by accelerating the commercialization of breakthrough healthcare technologies[1][2][4].
Looking ahead, aMoon is poised to deepen its impact by expanding its portfolio in emerging areas like precision medicine, AI-driven diagnostics, and novel therapeutics. Trends such as increased digital health adoption, regulatory support for innovation, and growing global healthcare needs will shape their journey. Their influence is likely to grow as they continue to bridge scientific discovery with market realities, helping startups scale and transform healthcare delivery worldwide. This aligns with their founding vision of harnessing technology and science to address some of the most pressing healthcare challenges of our time[1][2][4].
aMoon Fund has more than 26 tracked investments across 22 companies. The latest tracked deal is $52.0M Series C in Positive Development in August 2025.
